Filing Details
- Accession Number:
- 0001140361-16-085357
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-11-08 12:48:52
- Reporting Period:
- 2016-11-04
- Filing Date:
- 2016-11-08
- Accepted Time:
- 2016-11-08 12:48:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1444380 | Nevro Corp | NVRO | Surgical & Medical Instruments & Apparatus (3841) | 562568057 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1622421 | Michael Enxing | C/O Nevro Corp. 1800 Bridge Parkway Redwood City CA 94065 | Vp Of Sales | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-11-04 | 1,500 | $3.60 | 39,463 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-11-04 | 266 | $83.75 | 39,197 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-11-04 | 365 | $85.34 | 38,832 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-11-04 | 300 | $86.29 | 38,532 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-11-04 | 550 | $87.93 | 37,982 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-11-04 | 19 | $88.68 | 37,963 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2016-11-04 | 1,500 | $0.00 | 1,500 | $3.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
81,608 | 2022-12-17 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.30 to $84.28, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.81 to $85.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.97 to $86.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.68 to $88.34, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from December 1, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.